IMMUNOLOGIC PARAMETERS IN SYSTEMIC SCLEROSIS

International Journal of Dermatology

Volumn 33, Issue 1, 1994, Pages 25-32

  BRUNS, MARCO ^a   HERRMANN, KONRAD ^a   HAUSTEIN, UWE‐FRITHJOF ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SCHOOL CHILD; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; CENTROMERE; CHILD; FEMALE; FIBROBLASTS; HUMAN; INTERLEUKIN-2; MALE; MIDDLE AGE; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PROCOLLAGEN; RECEPTORS, INTERLEUKIN-2; SCLERODERMA, SYSTEMIC; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTE SUBSETS;

EID: 0027976645     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4362.1994.tb01488.x     Document Type: Article

References (64)

1. Cellular infiltrates in scleroderma skin
2. Pathogenesis of progressive systemic sclerosis
3. Systemic scleroderma. Clinical and pathophysiologic aspects
4. Diversity of anti‐nuclear antibodies in progressive systemic sclerosis. Anticentromere antibody and its relationship to CREST syndrome
5. Isolation of mononuclear cells and granulocytes from human blood
6. Serum levels of type III collagen aminopropeptide in patients with systemic sclereoderma
7. Are ACA and Scl 70 antibodies mutually exclusive
8. Autoantibodies in scleroderma
9. Clinical correlation and prognosis based on serum autoantibodies in patients with systemic sclerosis
10. Antinuclear antibodies in the relatives of patients with systemic sclero sis
11. Clinical significance of antinuclear antibodies in Japanese patients with systemic sclerosis
12. Die systemische Sklerodermie
13. Scleroderma: DR antigens, autoantibodies and clinical manifestations
14. Pulmonary involvement in systemic sclerosis
15. Systemic sclerosis (scleroderma): clinical, genetic, and serologic subsets
16. The IgG, IgM, and IgA isotypes of anti‐topoisomerase I and anticentromere autoantibodies
17. Clinical distribution of anticentromere antibody in Japanese patients
18. Kernantikörper als serologische Marker der progressiv systemischen Sklerodermie (PSS)
19. Anticentromere antibody. Clinical correlation and association with favorable prognosis in patients with scleroderma variants
20. Die Sklerodermien
21. Anticentromere antibody in patients with out CREST and scleroderma: association with active digital vasculitis, rheumatic and connective tissue disease
22. Longitudinal study of patients with anticentromere antibody
23. Early detection of connective tissue disease in patients with Raynaud's phenomenon
24. Early detection of scleroderma spectrum disorders in patients with Raynaud's phenomenon
25. Theophylline‐resistant and theophylline sensitive “active” and “total” E rosette‐forming lymphocytes in patients with systemic scleroderma
26. Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis
27. Defective CD2 pathway T‐cell activation in systemic lupus erythematosus
28. Immunoregulatory T cell subpopulations in patients with scleroderma using monoclonal antibodies
29. Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis
30. T lymphocyte subset abnormalities and HLA antigens in scleroderma (systemic sclerosis)
31. Normal immune responses in systemic sclerosis
32. Reduced natural killer cell activity in patients with systemic sclerosis
33. Natural killer cell activity of peripheral blood mononuclear cells from patients with various forms of systemic scleroder ma
34. EP. Treatment of cutaneous sclerosis and aplastic anaemia with antithymocyte globulin
35. Long‐term immunomodulatory effects of T lymphocyte depletion in patients with systemic sclerosis
36. Lymphocytotoxic autoantibodies in progressive systemic sclerosis
37. Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D‐penicillamine therapy
38. Enhanced expression of high‐affinity Interleukin‐2 receptors in scleroderma: possible role for IL‐6
39. Increased proto‐oncogene expression in peripheral blood T lymphocytes from patients with systemic sclerosis
40. The role of Interleukin‐2 in autoimmunity
41. Soluble Interleukin‐2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations
42. Interleukin‐2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration
43. Interleukin‐1, interleukin‐2, interleukin‐4, interleukin‐6, tumour necrosis factor α, and interferon‐gamma levels in sera from patients with scleroderma
44. A progress report on the treatment of 157 patients with advanced cancer using lymphokine‐activated killer cells and inter leukin‐2 of high‐dose interleukin‐2 alone
45. Interleukin‐2 activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis
46. Interactions and biological mechanisms of action of molecular signal peptides: interleukin 2 (IL‐2)
47. The soluble interleukin‐2 receptor: biology, function, and clinical application
48. Soluble in terleukin‐2 receptor, interleukin‐2 and interleukin‐4 in sera and supernatants from patients with progressive systemic sclerosis
49. Soluble immunologic products in scleroderma sera
50. Soluble interleukin‐2 receptor in juvenile rheumatoid arthritis
51. Changes in plasma levels of interleukin‐2 receptor in relation to disease exacerbations and levels of anti‐dsDNA and complement in systemic lupus erythematosus
52. Serum soluble interleukin‐2 receptor in systemic lupus erythematosus: effects of disease activity and infection
53. The release interleukin‐2 receptor binds interleukin‐2 efficiently
54. Soluble interleukin‐2 receptors inhibit interleukin‐2 dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T‐cell lymphomas in vivo
55. Soluble interleukin‐2 receptors released from mitogen stimulated human peripheral blood lymphocytes bind interleukin‐2 and inhibit IL‐2 dependent cell proliferation
56. In vivo administration of purified human interleukin‐2 to patients with cancer: development of interleukin‐2 receptor positive cells and circulating soluble interleukin‐2 receptors following interleukin‐2 administration
57. Role of lymphotoxin in expression of interleukin‐6 in human fibroblasts
58. Eate on inter leukin‐6 in the rat
59. Biological and clinical aspects of interleukin‐6
60. Interleukin‐6: historical background, genetics and biological significance
61. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts
62. Abnormalities of T lymphocyte subsets in systemic sclerosis demonstrated with anti‐CD45RA and anti‐CD29 monoclonal anti bodies
63. Autostimulatory effects of IL‐6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL‐6 production and IL‐6R expression
64. Increased interleukin‐2 production in response to human type I collagen stimulation in patients with systemic sclerosis